This trial is evaluating whether hMSC will improve 1 primary outcome and 1 secondary outcome in patients with COVID-19. Measurement will happen over the course of 14 days post treatment.
This trial requires 40 total participants across 2 different treatment groups
This trial involves 2 different treatments. HMSC is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
The incidence of severe disease will be reduced, but not entirely eliminated due to the persistence of some disease. In view of the low level of immunity to this novel coronavirus, patients with mild disease can develop severe disease. A significant proportion of people with mild disease will have severe disease and need intensive care. Therefore, an effective vaccine can be developed against this new virus. Also, given the similarity in disease courses of both MERS and SARS coronavirus infections, an effective coronavirus treatment may also be achievable.
Covid-Related Diseases and Infection will cause the loss of life and livelihood for many infected people and those with close contact. The virus is an infectious disease caused by a virus called Severe acute respiratory syndrome virus (SARS-CoV). The virus has caused worldwide health concerns, especially in East Asia. The virus causes a number of symptoms from mild flu-like symptoms to severe pneumonia which can be fatal for some people. The virus spreads easily as a droplet virus and infects people from contact with an infected person.
The U.S. Centers for Disease Control and Prevention (CDC) is planning to update weekly on the case count and hospitalizations from April 17, 2019 until May 10, 2019. The goal of this website is to help clinicians understand how many people are being affected by the outbreak and help them to make the best decision for each patient. This information is also helpful for patients, their loved ones, and their health care providers.\n
The virus causes respiratory distress and inflammation in humans. People, especially those who have an underlying health condition, are more severely affected. There is an association between cough syndrome and acute exacerbation of COPD. The virus may have previously been present in a person's respiratory tract. While the virus is highly infectious in humans, it is not transmissible mechanically or from person to person. There is currently no treatment for the virus, although the immune system may prevent people with respiratory infection from developing acute respiratory distress syndrome. The virus has been present in humans for several months before it became symptomatic in Wuhan, China, in January 2020.
Symptoms most commonly involve weakness, fatigue, loss of appetite, fever, cough, chest pain, headache, lethargy, feeling nauseous, vomiting, diarrhea, loss of appetite, chills, coughing up blood, and loss of taste. In some cases it may present with coughing up blood, chest pain, dizziness, difficulty breathing or fainting. While there are no specific cure for the coronavirus, symptoms can be treated with antihistamines (e.g., omalizumab or levocetirizine), a combination of cold liquids and antihistamines such as fexofenadine or hydroxyzine.
There are several common treatments for COVID-19, including supportive care and antiviral medications. There is uncertainty in the literature to determine when people should seek medical attention for symptoms of illness. The National Advisory Committee for Aeronautics recommends “to be evaluated by a health care professional as soon as symptoms occur and not wait for lab test results or to self-diagnose” for people without symptoms. There is also uncertainty around the benefits of staying home from work or school when you feel ill and there may be adverse health effects including transmission to others. As new information breaks out for treatment strategies and clinical guidelines, this page will be updated to reflect these recommendations and to include additional links to the right source.
This is the first study of self-reported adverse effects using the Hmsc, and the results suggest that the Hmsc is safe for people with MS-E. This is supported by the results of the short follow-up period in which we took no adverse effects reported out of the Hmsc survey.
The main cause of covid-19 is human-to-human transmission between people with respiratory symptoms, who are most likely to be in contact with a infected person (i.e., someone who is contagious to a person who has symptoms of an upper respiratory tract infection) in the early stages of the viral infection that becomes serious (called 'critically ill'). It is possible to accurately and efficiently monitor and treat those with mild symptoms of covid-19 in the community, because there is evidence it does not cause lifelong immunity and because most symptomatic infections will not be fatal. However, current evidence in China suggests there is at least one other cause of severe disease, namely the use of an inappropriate type of medical treatment.
Horseshoe bats represent the smallest mammalian native reservoir for infectious hv/hun viruses. The presence of hmsc-like viroids as the only known hv/hun-encoded ribosomal frame-shifting events in bat genomes supports their importance in the evolutionary history of the hv/hun virome.
Treatment of patients with COVID-19 should begin with antiviral drug treatment based on the disease type. Asymptomatic treatments should be avoided, and patients should be monitored for potential exacerbation of the disease. COVID-19-related fatalities have been reported in many countries and the number of fatalities is likely to rise. There is no specific treatment for any form of acute respiratory infection. Potential therapies include antimalarial agents such as chloroquine, hydroxychloroquine, and lopinavir-ritonavir; as well as antihistamines such as cetirizine, ebastine, and loratadine.
There have been no new treatments developed specifically for the treatment of covid-19, but there will undoubtedly be treatments that have been developed, based on the viral mechanisms that are being studied. Most treatment strategies have been developed for other viral infections such as HIV and influenza, therefore, it should not be surprising that, as new studies are published, treatments are being developed for the virus. There is no approved vaccine to mitigate the effects of covid-19, but there is potential that one can be developed in the future, and would be a significant advantage as part of a first line of defence against the pandemic strain.
In SARS, Hmsc is commonly combined with other treatments such as ritonavir as part of the standard care. Results from a recent paper have important implications for the development of clinical trials of treatments for this disease.